A Randomized, Naturalistic, Parallel-Group Study for the Long-Term Treatment of Panic Disorder With Clonazepam or Paroxetine
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
11/09/2013
11/09/2013
2012
|
Resumo |
This long-term extension of an 8-week randomized, naturalistic study in patients with panic disorder with or without agoraphobia compared the efficacy and safety of clonazepam (n = 47) and paroxetine (n = 37) over a 3-year total treatment duration. Target doses for all patients were 2 mg/d clonazepam and 40 mg/d paroxetine (both taken at bedtime). This study reports data from the long-term period (34 months), following the initial 8-week treatment phase. Thus, total treatment duration was 36 months. Patients with a good primary outcome during acute treatment continued monotherapy with clonazepam or paroxetine, but patients with partial primary treatment success were switched to the combination therapy. At initiation of the long-term study, the mean doses of clonazepam and paroxetine were 1.9 (SD, 0.30) and 38.4 (SD, 3.74) mg/d, respectively. These doses were maintained until month 36 (clonazepam 1.9 [ SD, 0.29] mg/d and paroxetine 38.2 [SD, 3.87] mg/d). Long-term treatment with clonazepam led to a small but significantly better Clinical Global Impression (CGI)-Improvement rating than treatment with paroxetine (mean difference: CGI-Severity scale -3.48 vs -3.24, respectively, P = 0.02; CGI-Improvement scale 1.06 vs 1.11, respectively, P = 0.04). Both treatments similarly reduced the number of panic attacks and severity of anxiety. Patients treated with clonazepam had significantly fewer adverse events than those treated with paroxetine (28.9% vs 70.6%, P < 0.001). The efficacy of clonazepam and paroxetine for the treatment of panic disorder was maintained over the long-term course. There was a significant advantage with clonazepam over paroxetine with respect to the frequency and nature of adverse events. Brazilian Council for Scientific and Technological Development (CNPq) Brazilian Council for Scientific and Technological Development (CNPq) National Institute for Translational Medicine (INCT-TM) National Institute for Translational Medicine (INCTTM) |
Identificador |
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, PHILADELPHIA, v. 32, n. 1, pp. 120-126, FEB, 2012 0271-0749 http://www.producao.usp.br/handle/BDPI/33257 10.1097/JCP.0b013e31823fe4bd |
Idioma(s) |
eng |
Publicador |
LIPPINCOTT WILLIAMS & WILKINS PHILADELPHIA |
Relação |
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY |
Direitos |
closedAccess Copyright LIPPINCOTT WILLIAMS & WILKINS |
Palavras-Chave | #CLONAZEPAM #PAROXETINE #PANIC DISORDER #PANIC ATTACKS #DOUBLE-BLIND #AGORAPHOBIA #DISCONTINUATION #EFFICACY #PLACEBO #BENZODIAZEPINES #PHARMACOTHERAPY #EPIDEMIOLOGY #WITHDRAWAL #ISSUES #PÂNICO #MANIFESTAÇÕES NEUROCOMPORTAMENTAIS #FARMACOTERAPIA #PHARMACOLOGY & PHARMACY #PSYCHIATRY |
Tipo |
article original article publishedVersion |